Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

Diane V. Havlir, Michelle A. Kendall, Prudence Ive, Johnstone Kumwenda, Susan Swindells, Sarojini S. Qasba, Anne F. Luetkemeyer, Evelyn Hogg, James F. Rooney, Xingye Wu, Mina C. Hosseinipour, Umesh Lalloo, Valdilea G. Veloso, Fatuma F. Some, N. Kumarasamy, Nesri Padayatchi, Breno R. Santos, Stewart Reid, James Hakim, Lerato MohapiPeter Mugyenyi, Jorge Sanchez, Javier R. Lama, Jean W. Pape, Alejandro Sanchez, Aida Asmelash, Evans Moko, Fred Sawe, Janet Andersen, Ian Sanne

Research output: Contribution to journalArticle

409 Citations (Scopus)

Abstract

BACKGROUND: Antiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing for the initiation of ART when tuberculosis is diagnosed in patients with various levels of immune compromise is not known. METHODS: We conducted an open-label, randomized study comparing earlier ART (within 2 weeks after the initiation of treatment for tuberculosis) with later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis) in HIV-1 infected patients with CD4+ T-cell counts of less than 250 per cubic millimeter and suspected tuberculosis. The primary end point was the proportion of patients who survived and did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illness at 48 weeks. RESULTS: A total of 809 patients with a median baseline CD4+ T-cell count of 77 per cubic millimeter and an HIV-1 RNA level of 5.43 log10 copies per milliliter were enrolled. In the earlier-ART group, 12.9% of patients had a new AIDS-defining illness or died by 48 weeks, as compared with 16.1% in the later-ART group (95% confidence interval [CI], -1.8 to 8.1; P = 0.45). Among patients with screening CD4+ T-cell counts of less than 50 per cubic millimeter, 15.5% of patients in the earlier-ART group versus 26.6% in the later-ART group had a new AIDS-defining illness or died (95% CI, 1.5 to 20.5; P = 0.02). Tuberculosis-associated immune reconstitution inflammatory syndrome was more common with earlier ART than with later ART (11% vs. 5%, P = 0.002). The rate of viral suppression at 48 weeks was 74% and did not differ between the groups (P = 0.38). CONCLUSIONS: Overall, earlier ART did not reduce the rate of new AIDS-defining illness and death, as compared with later ART. In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death. (Funded by the National Institutes of Health and others; ACTG A5221 ClinicalTrials.gov number, NCT00108862.)

Original languageEnglish (US)
Pages (from-to)1482-1491
Number of pages10
JournalNew England Journal of Medicine
Volume365
Issue number16
DOIs
StatePublished - Oct 20 2011

Fingerprint

Virus Diseases
HIV-1
Tuberculosis
Secondary Prevention
CD4 Lymphocyte Count
Acquired Immunodeficiency Syndrome
T-Lymphocytes
Therapeutics
Group Psychotherapy
Immune Reconstitution Inflammatory Syndrome
Confidence Intervals
National Institutes of Health (U.S.)
RNA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Havlir, D. V., Kendall, M. A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S. S., ... Sanne, I. (2011). Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. New England Journal of Medicine, 365(16), 1482-1491. https://doi.org/10.1056/NEJMoa1013607

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. / Havlir, Diane V.; Kendall, Michelle A.; Ive, Prudence; Kumwenda, Johnstone; Swindells, Susan; Qasba, Sarojini S.; Luetkemeyer, Anne F.; Hogg, Evelyn; Rooney, James F.; Wu, Xingye; Hosseinipour, Mina C.; Lalloo, Umesh; Veloso, Valdilea G.; Some, Fatuma F.; Kumarasamy, N.; Padayatchi, Nesri; Santos, Breno R.; Reid, Stewart; Hakim, James; Mohapi, Lerato; Mugyenyi, Peter; Sanchez, Jorge; Lama, Javier R.; Pape, Jean W.; Sanchez, Alejandro; Asmelash, Aida; Moko, Evans; Sawe, Fred; Andersen, Janet; Sanne, Ian.

In: New England Journal of Medicine, Vol. 365, No. 16, 20.10.2011, p. 1482-1491.

Research output: Contribution to journalArticle

Havlir, DV, Kendall, MA, Ive, P, Kumwenda, J, Swindells, S, Qasba, SS, Luetkemeyer, AF, Hogg, E, Rooney, JF, Wu, X, Hosseinipour, MC, Lalloo, U, Veloso, VG, Some, FF, Kumarasamy, N, Padayatchi, N, Santos, BR, Reid, S, Hakim, J, Mohapi, L, Mugyenyi, P, Sanchez, J, Lama, JR, Pape, JW, Sanchez, A, Asmelash, A, Moko, E, Sawe, F, Andersen, J & Sanne, I 2011, 'Timing of antiretroviral therapy for HIV-1 infection and tuberculosis', New England Journal of Medicine, vol. 365, no. 16, pp. 1482-1491. https://doi.org/10.1056/NEJMoa1013607
Havlir, Diane V. ; Kendall, Michelle A. ; Ive, Prudence ; Kumwenda, Johnstone ; Swindells, Susan ; Qasba, Sarojini S. ; Luetkemeyer, Anne F. ; Hogg, Evelyn ; Rooney, James F. ; Wu, Xingye ; Hosseinipour, Mina C. ; Lalloo, Umesh ; Veloso, Valdilea G. ; Some, Fatuma F. ; Kumarasamy, N. ; Padayatchi, Nesri ; Santos, Breno R. ; Reid, Stewart ; Hakim, James ; Mohapi, Lerato ; Mugyenyi, Peter ; Sanchez, Jorge ; Lama, Javier R. ; Pape, Jean W. ; Sanchez, Alejandro ; Asmelash, Aida ; Moko, Evans ; Sawe, Fred ; Andersen, Janet ; Sanne, Ian. / Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. In: New England Journal of Medicine. 2011 ; Vol. 365, No. 16. pp. 1482-1491.
@article{396cd747e6f6432c907dfed423fce5a7,
title = "Timing of antiretroviral therapy for HIV-1 infection and tuberculosis",
abstract = "BACKGROUND: Antiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing for the initiation of ART when tuberculosis is diagnosed in patients with various levels of immune compromise is not known. METHODS: We conducted an open-label, randomized study comparing earlier ART (within 2 weeks after the initiation of treatment for tuberculosis) with later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis) in HIV-1 infected patients with CD4+ T-cell counts of less than 250 per cubic millimeter and suspected tuberculosis. The primary end point was the proportion of patients who survived and did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illness at 48 weeks. RESULTS: A total of 809 patients with a median baseline CD4+ T-cell count of 77 per cubic millimeter and an HIV-1 RNA level of 5.43 log10 copies per milliliter were enrolled. In the earlier-ART group, 12.9{\%} of patients had a new AIDS-defining illness or died by 48 weeks, as compared with 16.1{\%} in the later-ART group (95{\%} confidence interval [CI], -1.8 to 8.1; P = 0.45). Among patients with screening CD4+ T-cell counts of less than 50 per cubic millimeter, 15.5{\%} of patients in the earlier-ART group versus 26.6{\%} in the later-ART group had a new AIDS-defining illness or died (95{\%} CI, 1.5 to 20.5; P = 0.02). Tuberculosis-associated immune reconstitution inflammatory syndrome was more common with earlier ART than with later ART (11{\%} vs. 5{\%}, P = 0.002). The rate of viral suppression at 48 weeks was 74{\%} and did not differ between the groups (P = 0.38). CONCLUSIONS: Overall, earlier ART did not reduce the rate of new AIDS-defining illness and death, as compared with later ART. In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death. (Funded by the National Institutes of Health and others; ACTG A5221 ClinicalTrials.gov number, NCT00108862.)",
author = "Havlir, {Diane V.} and Kendall, {Michelle A.} and Prudence Ive and Johnstone Kumwenda and Susan Swindells and Qasba, {Sarojini S.} and Luetkemeyer, {Anne F.} and Evelyn Hogg and Rooney, {James F.} and Xingye Wu and Hosseinipour, {Mina C.} and Umesh Lalloo and Veloso, {Valdilea G.} and Some, {Fatuma F.} and N. Kumarasamy and Nesri Padayatchi and Santos, {Breno R.} and Stewart Reid and James Hakim and Lerato Mohapi and Peter Mugyenyi and Jorge Sanchez and Lama, {Javier R.} and Pape, {Jean W.} and Alejandro Sanchez and Aida Asmelash and Evans Moko and Fred Sawe and Janet Andersen and Ian Sanne",
year = "2011",
month = "10",
day = "20",
doi = "10.1056/NEJMoa1013607",
language = "English (US)",
volume = "365",
pages = "1482--1491",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "16",

}

TY - JOUR

T1 - Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

AU - Havlir, Diane V.

AU - Kendall, Michelle A.

AU - Ive, Prudence

AU - Kumwenda, Johnstone

AU - Swindells, Susan

AU - Qasba, Sarojini S.

AU - Luetkemeyer, Anne F.

AU - Hogg, Evelyn

AU - Rooney, James F.

AU - Wu, Xingye

AU - Hosseinipour, Mina C.

AU - Lalloo, Umesh

AU - Veloso, Valdilea G.

AU - Some, Fatuma F.

AU - Kumarasamy, N.

AU - Padayatchi, Nesri

AU - Santos, Breno R.

AU - Reid, Stewart

AU - Hakim, James

AU - Mohapi, Lerato

AU - Mugyenyi, Peter

AU - Sanchez, Jorge

AU - Lama, Javier R.

AU - Pape, Jean W.

AU - Sanchez, Alejandro

AU - Asmelash, Aida

AU - Moko, Evans

AU - Sawe, Fred

AU - Andersen, Janet

AU - Sanne, Ian

PY - 2011/10/20

Y1 - 2011/10/20

N2 - BACKGROUND: Antiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing for the initiation of ART when tuberculosis is diagnosed in patients with various levels of immune compromise is not known. METHODS: We conducted an open-label, randomized study comparing earlier ART (within 2 weeks after the initiation of treatment for tuberculosis) with later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis) in HIV-1 infected patients with CD4+ T-cell counts of less than 250 per cubic millimeter and suspected tuberculosis. The primary end point was the proportion of patients who survived and did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illness at 48 weeks. RESULTS: A total of 809 patients with a median baseline CD4+ T-cell count of 77 per cubic millimeter and an HIV-1 RNA level of 5.43 log10 copies per milliliter were enrolled. In the earlier-ART group, 12.9% of patients had a new AIDS-defining illness or died by 48 weeks, as compared with 16.1% in the later-ART group (95% confidence interval [CI], -1.8 to 8.1; P = 0.45). Among patients with screening CD4+ T-cell counts of less than 50 per cubic millimeter, 15.5% of patients in the earlier-ART group versus 26.6% in the later-ART group had a new AIDS-defining illness or died (95% CI, 1.5 to 20.5; P = 0.02). Tuberculosis-associated immune reconstitution inflammatory syndrome was more common with earlier ART than with later ART (11% vs. 5%, P = 0.002). The rate of viral suppression at 48 weeks was 74% and did not differ between the groups (P = 0.38). CONCLUSIONS: Overall, earlier ART did not reduce the rate of new AIDS-defining illness and death, as compared with later ART. In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death. (Funded by the National Institutes of Health and others; ACTG A5221 ClinicalTrials.gov number, NCT00108862.)

AB - BACKGROUND: Antiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing for the initiation of ART when tuberculosis is diagnosed in patients with various levels of immune compromise is not known. METHODS: We conducted an open-label, randomized study comparing earlier ART (within 2 weeks after the initiation of treatment for tuberculosis) with later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis) in HIV-1 infected patients with CD4+ T-cell counts of less than 250 per cubic millimeter and suspected tuberculosis. The primary end point was the proportion of patients who survived and did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illness at 48 weeks. RESULTS: A total of 809 patients with a median baseline CD4+ T-cell count of 77 per cubic millimeter and an HIV-1 RNA level of 5.43 log10 copies per milliliter were enrolled. In the earlier-ART group, 12.9% of patients had a new AIDS-defining illness or died by 48 weeks, as compared with 16.1% in the later-ART group (95% confidence interval [CI], -1.8 to 8.1; P = 0.45). Among patients with screening CD4+ T-cell counts of less than 50 per cubic millimeter, 15.5% of patients in the earlier-ART group versus 26.6% in the later-ART group had a new AIDS-defining illness or died (95% CI, 1.5 to 20.5; P = 0.02). Tuberculosis-associated immune reconstitution inflammatory syndrome was more common with earlier ART than with later ART (11% vs. 5%, P = 0.002). The rate of viral suppression at 48 weeks was 74% and did not differ between the groups (P = 0.38). CONCLUSIONS: Overall, earlier ART did not reduce the rate of new AIDS-defining illness and death, as compared with later ART. In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death. (Funded by the National Institutes of Health and others; ACTG A5221 ClinicalTrials.gov number, NCT00108862.)

UR - http://www.scopus.com/inward/record.url?scp=80054721877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054721877&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1013607

DO - 10.1056/NEJMoa1013607

M3 - Article

C2 - 22010914

AN - SCOPUS:80054721877

VL - 365

SP - 1482

EP - 1491

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 16

ER -